Docket No.: E0196.0100

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Franz Klug et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Examiner: Not Yet Assigned

Filed: Concurrently Herewith

Art Unit: N/A

( )

For: METHOD AND DEV

METHOD AND DEVICE FOR PROTECTED TRANSMISSION OF DATA

WORDS

## INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

This IDS is being filed before the First Office Action<sup>1</sup>.

<sup>&</sup>lt;sup>1</sup> The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

App	olication No.: Not Yet Assigned	Docket No.: E0196.0100
	This IDS is being filed after the issuance of the First Off issuance of a Final Office Action <sup>2</sup> .	ice Action but before the
	This IDS is being filed after the issuance of a Final Office	e Action, Ex Parte Quayle
	Action or Notice of Allowance but before the payment	
Cert	ifications:	
If ch	ecked, the undersigned makes the following statement(s):	
	Statement under 37 CFR § 1.97(c):	
	Each item of information contained in this information	disclosure statement was
	first cited in any communication from a foreign patent of	office in a counterpart
	foreign application not more than three months prior to	the filing of this
	information disclosure statement; or	
	No item of information contained in this information di	sclosure statement was
	cited in a communication from a foreign patent office in	a counterpart foreign
	application, and, to the knowledge of the undersigned a	fter making reasonable
	inquiry, no item of information contained in this inform	ation disclosure
	statement was known to any individual designated in §	1.56(c) more than three
	months prior to the filing of the information disclosure s	statement.
	Statement Under 37 C.F.R. § 1.704(d):	
	<sup>2</sup> The IDS must include either a certification under 37 C.F.R. §1.97(e)	or the fee set forth in 37 C.F.R.

()

<sup>§1.17(</sup>p).

The IDS must include both a certification under 37 C.F.R. §1.97(e) and the fee set forth in 37

C.F.R. §1.17(p).

Application No.: Not Yet Assigned

Docket No.: E0196.0100

( )

	Each item of information contained in this information disclosure statement was
	cited in a communication from a foreign patent office in a counterpart
	application less than thirty days prior to the filing of this information disclosure
 	statement
Fee I	Required by 37 C.F.R. § 1.97(c)(2) or 1.97(d)(2):
	If checked, the fee of \$180.00 set forth in 37 C.F.R. \$1.17(p) is attached.
Copi	es of Information:
In acc	cordance with 37 C.F.R. §1.98(a), the following are enclosed:
$\boxtimes$	A legible copy <sup>4</sup> of each document (or relevant portion thereof) cited in the
	attached PTO/SB/08, except for U.S. patent and U.S. published applications.
	With respect to any information which is not in English, a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, is attached. This concise explanation is provided by way of:
	A translation of the relevant portions of the non-English language information <sup>5</sup> ;
	A statement explaining the relevant portions of the non-English language information;

<sup>4</sup> A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) – (c). This exception does not apply to information cited in an International Application.

	A copy [and, where not in the English language, a translation] of at
le	east the relevant portion(s) of the communication from a foreign patent
of	ffice in a counterpart foreign application in which the information was
di	ted; or
E ap	This information is contained in the specification of the present oplication.
In accord	lance with 37 C.F.R. 1.98(d), copies of the cited documents are not
enclosed as they	y were provided in application Serial No. , , filed ,
which the prese	ent application relies upon for an earlier effective filing date under 35
U.S.C. 120.	

( )

## Materiality:

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

<sup>5 37</sup> C.F.R. §1.98(a)(3)(ii) requires that an English language translation be provided when a translation of the document, or portion thereof, "is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c)."

<sup>&</sup>lt;sup>6</sup> The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an "X", "Y", or "A" indication on a search report. MPEP §609 III A(3).

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: March 20, 2006

Respectfully submitted,

Laura C. Brutman

Registration No.: 38,395

DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP

1177 Avenue of the Americas

41st Floor

New York, New York 10036-2714

(212) 835-1400

Attorney for Applicant

Substitute for form 1449/PTO		Complete if Known						
INFORMATION DISCLOSURE							Application Number	Not Yet Assigned
					SCLO	SURE	Filing Date	Concurrently Herewith
STATEMENT BY APPLICANT		First Named Inventor	Franz Klug					
						Art Unit	N/A	
(Use as many sheets as necessary)			)	Examiner Name	Not Yet Assigned			
Sheet	-	1		of-		1	Attorney Docket Number	E0196:0100

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/E.A./	AA*	US-5,485,474			r igures/ppear
/E.A./	AB*	US-5,307,409			

		FOREIG	GN PATENT I	DOCUMENTS		7
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T.
	L					Н

"EXAMINE: Initial it information considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and not considered, hashes copy at this time with next communication is applicant." Applicant's unique citation designation number (optional). "See Kinals Codes of USPTO Patient Document, and the MPEP 901 01.0. "Direct Ribos that issued the document, by the hot-letter code (MPO) Standard 513..." For heappropriate symbols as indicated on the document under WIPO Standard 51.4 "For the paper patient period is to piece a other character as the patient standard in the patient course." When the patient is a piece a other character as far given the patient standard in the patient with patient standard in the patient character as the patient with the patient in the patient standard in the patient with the patient in the patient standard in the patient with the patient in the patient standard in the patient with the patient in the patient with the patient in the patient with the patient patient in the patient patient with the patient patient in the patient patie

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	No.'	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/E.A./	ICA	Dufour, J-L.: "Safety computations in integrated circuits"	+-

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.